Leqembi

A Biogen facility in Cambridge, Massachusetts.Brian Snyder | ReutersBiogen on Tuesday said it expects to cut approximately 1,000 jobs, or about 11% of its workforce, to save costs as the biotech company prepares to launch its newly approved…

<!-- -->Approximately 6.5 million Americans suffer from Alzheimer's (Representational)The US drug regulator gave full approval to a new Alzheimer's medicine on Thursday, a move that makes it more widely available to the public through…

The Alzheimer's drug Leqembi is seen in this undated handout image obtained by Reuters on January 20, 2023.Eisai | via ReutersMedicare has agreed to pay for the Alzheimer's treatment Leqembi, a major turning point for patients who are…

U.S. officials granted full approval to a closely watched Alzheimer's drug on Thursday, clearing the way for Medicare and other insurance plans to begin covering the treatment for people with the brain-robbing disease.The Food and Drug…

Jay Reinstein, who suffers from Alzheimer's, receives an injection so he can have a PET scan at MedStar Georgetown University Hospital in Washington, DC on June 20, 2023. Michael Robinson Chávez | The Washington Post | Getty ImagesSales of…

The Food and Drug Administration granted full approval for the most effective drug to attack Alzheimer’s disease in decades.The decision from federal regulators follows a unanimous recommendation by neurologists at the agency last month and…

On Thursday, the Food and Drug Administration gave full approval to the drug Leqembi for patients who are in the early stages of Alzheimer’s disease, and Medicare said it would cover 80 percent of the cost of the $26,500-per-year…

The Food and Drug Administration on Thursday approved the Alzheimer's treatment Leqembi, a pivotal decision that is expected to expand access to the expensive drug for older Americans.Medicare has promised to start covering Leqembi, with…

The Food and Drug Administration on Thursday gave full approval to the Alzheimer’s drug Leqembi, and Medicare said it would cover much of its high cost, laying the foundation for widespread use of a medication that can modestly slow…

A panel of independent advisors to the Food and Drug Administration is meeting Friday to make a recommendation on whether the Alzheimer's drug Leqembi, made by Eisai and Biogen, should receive full approval.The FDA is not required to follow…